Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature

American Journal of Health-System Pharmacy

Volumn 67, Issue 3, 2010, Pages 206-213

  Ward, Kristina E ^a   Archambault, Raoul ^b   Mersfelder, Tracey L ^c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Robert E Bush Naval Hospital Twentynine Palms   (United States)

^c FERRIS STATE UNIVERSITY   (United States)

Author keywords

Antiinflammatory agents; Epidermal necrolysis; Geriatrics; Sex; Stevens johnson syndrome; Toxicity

Indexed keywords

CELECOXIB; CORTICOSTEROID DERIVATIVE; DICLOFENAC; DIFLUNISAL; ETODOLAC; ETORICOXIB; FENOPROFEN; FUROSEMIDE; IBUPROFEN; INDOMETACIN; ISOXICAM; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SALSALATE; SULFADIAZINE SILVER; SULINDAC; TENOXICAM; TOLMETIN; UNINDEXED DRUG; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ATTRIBUTABLE RISK; BEDTIME DOSAGE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNITED STATES; AGE; CHEMICALLY INDUCED DISORDER; DRUG SURVEILLANCE PROGRAM; FEMALE; MALE; SEX DIFFERENCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; RISK FACTORS; SEX FACTORS; STEVENS-JOHNSON SYNDROME;

EID: 77449091896     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp080603     Document Type: Review

References (48)

1. Morelli MS, O'Brien FX. Stevens Johnson syndrome and cholestatic hepatitis. Dig Dis Sci. 2001; 46:2385-8. (Pubitemid 33042337)
2. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333:1600-7.
3. Mockenhaupt M, Kelly JP, Kaufman D et al., for the SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal anti-inflammatory drugs: a multinational prospective. J Rheumatol. 2003; 30:2234-40. (Pubitemid 37221857)
4. Small RE, Garnett WR. Sulindac-induced toxic epidermal necrolysis. Clin Pharm. 1988; 7:766-71.
5. Strom BL, Carson JL, Halpern AC et al. A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol. 1991; 127:831-8.
6. Chan HL, Stern RS, Arndt KA et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990; 126:43-7.
7. Chan JC, Lai FM, Critchley JA. A case of Stevens-Johnson syndrome, cholestatic hepatitis and haemolytic anaemia associated with use of mefenamic acid. Drug Saf. 1991; 16:230-4.
8. Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. www.fda.gov/bbs/topics/ news/2004/NEW01122.html (accessed 2007 Nov 14).
9. Food and Drug Administration. Alert for healthcare professionals: celecoxib (marketed as Celebrex). www.fda.gov/cder/drug/infopage/celebrex/ celebrex-hcp.pdf (accessed 2007 Nov 14).
10. Food and Drug Administration. FDA talk paper: Bextra label updated with boxed warning concerning severe skin reactions and warning regarding cardiovascular risk. www.fda.gov/bbs/topics/ANSWERS/2004/ANS01331.html (accessed 2005 Dec 11).
11. Gardner A. Ibuprofen controversy continues after COX-2 hearings. www.hon.ch/News/HSN/524149.html (accessed 2005 Dec 11).
12. Guillaume JC, Roujeau JC, Revuz J et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987; 123:1166-70.
13. Schopf E, Stuhmer A, Rzany B et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991; 127:839-42.
14. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129:92-6.
15. World Health Organization. About the ATC/DDD system. www.whocc.no/atcddd/ atcsystem.html (accessed 2007 Nov 19).
16. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45. (Pubitemid 12149145)
17. La Grenade L, Lee L, Weaver J et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005; 28:917-24. (Pubitemid 41428548)
18. Ikeda N, Umetsu K, Suzuki T. A fatal case of sulindac-induced Lyell syndrome (toxic epidermal necrolysis). Z Rechtsmed. 1987; 98:141-6. (Pubitemid 17115118)
19. Roupe G, Ahlmen M, Fagerberg B et al. Toxic epidermal necrolysis with extensive mucosal erosions of the gastrointestinal and respiratory tracts. Int Arch Allergy Appl Immunol. 1986; 80:145-51. (Pubitemid 16109945)
20. Klein SM, Khan MA. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy. J Rheumatol. 1983; 10:512-3. (Pubitemid 13014440)
21. Park GD, Spector R, Headstream T et al. Serious adverse reactions associated with sulindac. Arch Intern Med. 1982; 142:1292-4.
22. Maguire FW. Stevens-Johnson syndrome due to sulindac: a case report and review of literature. Del Med J. 1981; 53:193-7.
23. Husain Z, Runge LA, Jabbs JM et al. Sulindac-induced Stevens-Johnson syndrome: a report of 3 cases. J Rheumatol. 1981; 8:176-9.
24. Levitt L, Pearson RW. Sulindac-induced Stevens-Johnson toxic epidermal necrolysis syndrome. JAMA. 1980; 243:1262-3. (Pubitemid 10130195)
25. O'Sullivan D, Hanly JG, Molloy M. A case of toxic epidermal necrolysis secondary to indomethacin. Br J Rheumatol. 1983; 22:47-9. (Pubitemid 13157630)
26. Lear JT, English JS. Toxic epidermal necrolysis associated with indomethacin therapy. Postgrad Med J. 1996; 72:186-7. (Pubitemid 26089427)
27. Stotts JS, Fang ML, Dannaker CJ et al. Fenoprofen-induced toxic epidermal necrolysis. J Am Acad Dermatol. 1988; 18(4, pt 1):755-7.
28. Taghian M, Tran TA, Bresson-Hadni S et al. Acute vanishing bile duct syndrome after ibuprofen therapy in a child. J Pediatr. 2004; 145:273-6. (Pubitemid 38993407)
29. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndrome in a child. Gastroenterology. 1998; 115:743-6. (Pubitemid 28397310)
30. Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. N Y State J Med. 1978; 78:1239-43. (Pubitemid 8395512)
31. Tijhuis GJ, Teepe RG, Smith SJ. Toxic epidermal necrolysis related to ketoprofen. Dermatology. 1995; 190:176. Letter.
32. Reichenberg JS, Davis MD. Picture of the month. Stevens-Johnson syndrome. Arch Pediatr Adolesc Med. 2006; 160:801-2.
33. Mansur AT, Aydingoz IA. A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin. Photodermatol Photoimmunol Photomed. 2005; 21:100-2. (Pubitemid 40425655)
34. Ting W, Stone MS, Racila D et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004; 13:941-50. (Pubitemid 39664954)
35. Barrera JE, Meyers AD, Hartford EC. Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis. Arch Otolaryngol Head Neck Surg. 1998; 124:1375-6. (Pubitemid 28564114)
36. Kalemoglu M, Kiskin O. Naproxen sodium-induced toxic epidermal necrolysis: a case report and review of the literature. Eur Surg. 2005; 37:343-7. (Pubitemid 43099069)
37. Carucci JA, Cohen DE. Toxic epidermal necrolysis following treatment with oxaprozin. Int J Dermatol. 1999; 38:233-4. (Pubitemid 29155369)
38. Bell MJ, Bishara LD. A case of Stevens-Johnson syndrome associated with oxaprozin therapy. J Rheumatol. 1998; 25:2026-8. (Pubitemid 28459323)
39. Paul CN, Voigt DW, Clyne KE et al. Case report: oxaprozin and fatal toxic epidermal necrolysis. J Burn Care Rehabil. 1998; 19:321-3. (Pubitemid 28364590)
40. Yusin JS, Crawford WW, Klaustermeyer WB. Facial edema, oral ulcers, and a cutaneous eruption following a dental procedure utilizing diflunisal and mepivacaine. Ann Allergy Asthma Immunol. 1999; 83:353-5.
41. Hunter JA, Dorward AJ, Knill-Jones R et al. Diflunisal and Stevens-Johnson syndrome. Br Med J. 1978; 2:1088. Letter.
42. Layton D, Marshall V, Boshier A et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006; 29:687-96. (Pubitemid 44175039)
43. Berger P, Dwyer D, Corallo CE. Toxic epidermal necrolysis after celecoxib therapy. Pharmacotherapy. 2002; 22:1193-5. (Pubitemid 34969076)
44. Friedman B, Orlet HK, Still JM et al. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). South Med J. 2002; 95:1213-4. (Pubitemid 35244846)
45. Perna AG, Woodruff CA, Markus RF et al. Toxic epidermal necrolysis as a complication of treatment with celecoxib. Dermatol Online J. 2003; 9(5):25.
46. Goldberg D, Panigrahi D, Barazi M et al. A case of rofecoxib-associated Stevens-Johnson syndrome with corneal and conjunctival changes. Cornea. 2004; 23:736-7.
47. Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy. 2003; 23:551-3. (Pubitemid 36384336)
48. Paulose-Ram R, Hirsch R, Dillon C et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003; 12:315-26. (Pubitemid 36700608)